• In late June 2026, Celldex Therapeutics, Inc. was added to multiple Russell growth benchmarks, including the Russell 2000 Growth, 2500 Growth, 3000 Growth, 3000E Growth and Russell Small Cap Comp Growth indexes.
• This broad inclusion meaningfully increases Celldex’s visibility to institutional investors and index-tracking funds, potentially deepening liquidity and broadening its shareholder base.
• Next, we’ll examine how Celldex’s broad Russell growth index inclusion shapes its investment narrative and investor perception over the near term.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Celldex Therapeutics' Investment Narrative?

To own Celldex today, you really need to believe in the company’s ability to convert its barzolvolimab and CDX-622 programs into a viable commercial allergy and immunology business, despite very small current revenue and sizable ongoing losses. The near term story is still dominated by late 2026 Phase 3 CSU readouts for barzolvolimab, the asthma Phase 1b for CDX-622, and how efficiently Celldex deploys the roughly US$416 million raised across its April equity offering and the new US$115.91 million shelf. Broad Russell growth index inclusion and recent share price strength help on liquidity and access to capital, but they do not fundamentally change these core clinical and execution risks. If anything, higher visibility could sharpen the market’s reaction to any data disappointments or delays.

However, the company’s rising profile also amplifies one specific risk investors should not overlook. Celldex Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two Simply Wall St Community fair value views cluster around US$57.53 and US$100.82, underlining how far apart private investors can be. When you set that against Celldex’s ongoing losses and pivotal late stage trial risk, it becomes clear why taking in several viewpoints really matters before committing fresh capital.

Explore 2 other fair value estimates on Celldex Therapeutics - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Celldex Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Celldex Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celldex Therapeutics' overall financial health at a glance.

No Opportunity In Celldex Therapeutics?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.